FL-ASG-SOFTWARE
Accelerating the process by which businesses gain value from data, ASG Software Solutions today announced the launch of its Enterprise Data Intelligence solution. By empowering organizations to better understand the data that underpins operations, the solution enables agile, fact-based decision-making, improves compliance response time and accuracy, and supports automated impact analysis for better long-term corporate planning and strategy.
The increasing complexity and volume of enterprise data challenges companies to quickly identify critical data and turn it into real-world value. Vital information is locked up in departmental siloes, spread across legacy and modern systems, while the drive to digitalization forces businesses to move faster to satisfy stakeholders and achieve desired business outcomes. It takes too long to trace data, identify the source and ensure quality in response to immediate opportunities, compliance requests or strategic initiatives.
Combining the ability to mine and understand metadata with compiler-like parsing of discovered applications from more than 220 sources across mainframe, distributed and Hadoop-based systems, the Enterprise Data Intelligence solution provides an end-to-end view of an organization’s information estate to improve data visibility, analysis and understanding. The fully integrated solution also offers business glossary, data inventory, data governance and reference data tools to serve as an organization’s complete and comprehensive data repository, assuring the relevancy of critical data used in business processes.
“Every business sits on a treasure trove of data, but many lack a clear understanding of the origin, movements, volume, characteristics and quality of that data. Such gaps in enterprise data understanding can significantly slow innovation and response time to new threats or opportunities,” said Charles Sansbury, President and Chief Executive Officer, ASG Software Solutions. “Our new solution offers a unique patent pending combination of data lineage and data discovery tools to close those gaps. As a result, business and IT users gain more confidence in the data they rely on to support timely and strategic decisions, or to satisfy compliance responsibilities.”
From a single interface, business or IT users can discover, collect, organize, represent and better understand their data to support business decisions. Data stewards or compliance officers can reliably demonstrate data’s origin and transformation through the organization to satisfy compliance and audit requirements. Product leaders can benefit from rich impact analysis to scope new initiatives and limit the risk of missed opportunities.
The solution helps organizations in a range of verticals tackle data-driven challenges. Retailers can quickly find the data needed to pursue timely seasonal campaigns, and work with confidence and trust in their analytical data. Businesses and government agencies can establish a powerful metadata repository that automatically populates and stores an infinite number of versions and data snapshots. In regulated industries like finance and banking, businesses can confidently demonstrate sound risk management practices in response to compliance audits.
Features include:
- “Zero-Gap” data lineage – an industry-first approach to combining application discovery and data lineage
- A RESTful API Layer that allows interactive links and dynamic portability in and out of other governance or analytical tools and applications
- A new data governance and business applications model
- The ability to maintain distinct enterprise and line of business views of data and update each independently, with support for LOB onboarding
Our patent pending approach to Enterprise Data Intelligence enhances data understanding for enterprise risk and regulatory compliance initiatives, mergers and acquisitions, technology modernization projects and more. Learn more about Enterprise Data Intelligence by visiting www.asg.com/intelligence .
About ASG Software Solutions
ASG Software Solutions helps
customers with complex IT environments solve problems across the
enterprise. Its solutions empower businesses to enhance workforce
productivity, gain an accurate and timely understanding of the
information that underpins business decisions and address compliance
needs with improved visibility of cross-platform data. ASG can proudly
say that more than 70 percent of global Fortune 500 companies trust it
to optimize their existing IT investments. ASG is a global provider of
technology solutions with more than 1,000 people supporting a global
customer base across 4,000 midmarket and enterprise customers. For more
information, visit www.asg.com
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160322005802/en/
Contact:
ASG Software Solutions
Melissa McKee, +1-239-435-2277
melissa.mckee@asg.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom